Rhumbline Advisers Xtl Biopharmaceuticals LTD Call Options Transaction History
Rhumbline Advisers
- $109 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding XTLB
# of Institutions
5Shares Held
431KCall Options Held
0Put Options Held
0-
Noked Capital LTD Tel Aviv, L3199KShares$338,1090.02% of portfolio
-
Noked Israel LTD Ramat Hasharon, L3199KShares$338,1090.1% of portfolio
-
Morgan Stanley New York, NY26.5KShares$44,9660.0% of portfolio
-
Concourse Financial Group Securities, Inc. Birmingham, AL0Shares$00.0% of portfolio
About XTL BIOPHARMACEUTICALS LTD
- Ticker XTLB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 5,449,060
- Market Cap $9.26M
- Description
- XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Ye...